Quale sarebbe il prezzo per Sigilon Therapeutics, Inc. (SGTX)

Il prezzo per Sigilon Therapeutics, Inc. (SGTX) è $22.47

Qual è la capitalizzazione di mercato per Sigilon Therapeutics, Inc. (SGTX)

La capitalizzazione di mercato per Sigilon Therapeutics, Inc. (SGTX) è $49.76M

Utili di Sigilon Therapeutics, Inc. (SGTX)

Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.

Anno	Utile	Cambia
Non abbastanza dati per le date fornite.

Anno

Utile

Cambia

Non abbastanza dati per le date fornite.

Azienda	Utile	Differenza negli utili	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$-3.09B	-	US

Azienda

Utile

Differenza negli utili

Il paese